Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KAON CL vs MICRO-K LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Hypokalemia prevention or treatment,Diuretic-induced hypokalemia,Digitalis intoxication
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Not metabolized; excreted primarily via kidneys.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
None (K+ is free ion).
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
0.35 L/kg (approximate total body water; distributes primarily in extracellular fluid).
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
Oral: ~80-100% for microencapsulated KCl (MICRO-K), but can be incomplete due to slower release.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
GFR 50-90 m L/min: no adjustment. GFR 30-49 m L/min: reduce dose by 25-50%. GFR <30 m L/min: avoid use or reduce dose by 50-75% with close monitoring.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: avoid use or reduce dose by 50%.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
1-3 m Eq/kg/day orally in 2-4 divided doses; maximum 1 m Eq/kg per dose and 100 m Eq/day.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Initiate at lower end of dosing range (10-20 m Eq/day); monitor renal function and serum potassium frequently; adjust based on renal function.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
No black box warning.
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Risk of hyperkalemia especially in renal impairment,Use with caution in cardiac disease,GI irritation or ulceration with oral forms,Slow release formulations may cause GI lesions
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Hyperkalemia,Severe renal impairment,Untreated Addison's disease,Acute dehydration,Use of potassium-sparing diuretics
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, dried fruits, salt substitutes containing potassium chloride). Do not take with alcohol as it may increase GI irritation. Grapefruit juice has no significant interaction, but large amounts of any food high in potassium should be avoided.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
Potassium is a normal component of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: not applicable (endogenous electrolyte).
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
No dose adjustment typically required. Maintain serum potassium within normal range. Monitor for hypokalemia or hyperkalemia as clinically indicated.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
MICRO-K LS contains potassium chloride microencapsulated granules for sustained release. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min), untreated Addison's disease, or hyperkalemia. Use with caution in patients with cardiac disease or concurrent use of ACE inhibitors, ARBs, or potassium-sparing diuretics. Do not crush or chew capsules; administer with a full glass of water to prevent GI mucosal damage. Monitor serum potassium regularly, especially in elderly and diabetic patients.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
Take this medication exactly as prescribed, preferably with meals or a full glass of water.,Do not crush, chew, or break the capsules; swallow them whole.,Avoid foods high in potassium (e.g., bananas, oranges, tomatoes, salt substitutes) unless directed by your doctor.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, numbness/tingling, or dark/tarry stools.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KAON CL vs MICRO-K LS, answered by our medical review team.
KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. MICRO-K LS is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KAON CL and MICRO-K LS depend on the specific clinical indication. These are both Electrolyte Supplement (Potassium) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. The standard adult dose of MICRO-K LS is: 10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KAON CL and MICRO-K LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. MICRO-K LS is classified as Category C. MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.